Repligen financial statements require restatement due to revenue recognition error [Seeking Alpha]
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: Seeking Alpha
product revenue from a COVID-related cancellation payment was recognized inappropriately. The error has impacted financial statements for the year ended 2023, as well as fiscal quarters ended March 31, 2023 through June 30, 2024. Repligen noted that the change does not impact the total revenue recognized for this payment. The payment at the heart of the matter was a $17.3M cash payment received in April 2023 as a fee after a customer cancelled two COVID-related purchase orders. The company said it thought it had accounted for this appropriately based on U.S. GAAP practices and there was no fraud or misconduct involved. The "February 2023 transaction should have been analyzed and accounted for as a contract modification, which required this Payment to be deferred and recognized as product units were delivered under the Open PO," an SEC filing states. The document also noted that the restatement should not have an impact on business operations, cash and cash equivalent balan
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- Repligen Corporation to Present at Upcoming Investor ConferencesGlobeNewswire
- Repligen to Report Third Quarter 2024 Financial ResultsGlobeNewswire
- Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release [Yahoo! Finance]Yahoo! Finance
- Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More [Yahoo! Finance]Yahoo! Finance
- Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $205.00 price target on the stock.MarketBeat
RGEN
Earnings
- 7/30/24 - In-Line
RGEN
Sec Filings
- 10/23/24 - Form SC
- 9/18/24 - Form 8-K
- 9/12/24 - Form 4
- RGEN's page on the SEC website